Responses
Immune cell therapies and immune cell engineering
Original research
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT
Compose a Response to This Article
Other responses
No responses have been published for this article.